American Capital Management Inc. Acquires 22,605 Shares of Repligen Corporation $RGEN

American Capital Management Inc. lifted its holdings in Repligen Corporation (NASDAQ:RGEN) by 6.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 357,720 shares of the biotechnology company’s stock after acquiring an additional 22,605 shares during the quarter. Repligen makes up about 2.3% of American Capital Management Inc.’s holdings, making the stock its 18th largest holding. American Capital Management Inc.’s holdings in Repligen were worth $42,147,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Massachusetts Financial Services Co. MA bought a new position in Repligen in the fourth quarter worth approximately $199,176,000. M&T Bank Corp bought a new stake in Repligen during the 4th quarter valued at $29,819,000. Swedbank AB bought a new stake in Repligen during the 4th quarter valued at $4,146,000. Conestoga Capital Advisors LLC increased its holdings in shares of Repligen by 10.6% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock valued at $173,360,000 after acquiring an additional 101,062 shares during the period. Finally, Jennison Associates LLC purchased a new position in shares of Repligen in the 4th quarter valued at $20,253,000. 97.64% of the stock is currently owned by institutional investors.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RGEN shares. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, July 14th. Roth Capital began coverage on shares of Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 target price for the company. Barclays increased their price target on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Tuesday, July 7th. Finally, Wolfe Research assumed coverage on shares of Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $165.36.

Repligen Stock Performance

Shares of Repligen stock opened at $131.06 on Tuesday. The firm has a market capitalization of $7.39 billion, a P/E ratio of 145.62, a PEG ratio of 2.54 and a beta of 1.06. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average price of $132.21 and a 200 day moving average price of $132.05. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. Repligen’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same period last year, the business earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.